C3 and COVID-19: Clinical studies have provided evidences for strong complement activation in the serum and lungs of critically ill COVID-19 patients (2–4) and a few case reports have shown a beneficial effect of blocking complement at the levels of C3 or C5 components, which are involved in the generation of the pro-inflammatory C3a and C5a mediators (5–7).